Rare diseases
Investigational molecules
Locations
Theodor-Kutzer-Ufer 1-3, Wohlgelegen, 68167 Mannheim, Germany
Heidelberg University in Mannheim, Germany specialises in clinical trials of conditions such as Breast cancer, Crohn's disease, Malignant melanoma, Non-small cell lung cancer, and other specialisations. This site conducts important research.
At Heidelberg University the focus is on developing new therapies that lower the risk of heart attacks, strokes and other vascular events, aiming to improve long‑term survival and quality of life for patients with cardiovascular conditions.
More than 20 clinical trials are active in this therapeutic area, supported by a dedicated team of investigators working to evaluate safety and efficacy of innovative cardiovascular agents.
Researchers are testing novel biologics and small molecules to control inflammation and restore intestinal health, with the goal of achieving durable remission for patients with chronic gut disorders.
Approximately 15 trials explore therapeutic options ranging from immune‑modulating antibodies to targeted agents, with a multidisciplinary team of gastroenterology and oncology specialists.
The department conducts extensive studies on blood‑cancer therapies, seeking to improve remission rates and reduce treatment‑related toxicity for patients with leukemias, lymphomas and related disorders.
Over 25 trials evaluate targeted inhibitors, combination regimens and cellular therapies, driven by a cohort of hematology experts.
Studies aim to modulate aberrant immune responses, offering patients safer and more effective options for autoimmune and inflammatory conditions.
Around 10 trials focus on biologics, complement inhibitors and novel small molecules, with close collaboration between rheumatology, nephrology and neurology units.
A broad oncology program evaluates cutting‑edge treatments—including immunotherapies, antibody‑drug conjugates and precision‑targeted agents—to extend survival across a wide spectrum of solid tumours.
More than 30 active trials investigate efficacy and safety of novel regimens, with a strong emphasis on biomarker‑driven patient selection.
Clinical investigations target neurodegeneration and brain tumours, striving to slow disease progression and improve neurological function through innovative therapeutic approaches.
Approximately 12 trials explore gene‑targeted drugs, immunotherapies and neuroprotective agents, supported by specialized neuro‑oncology and neurology teams.
Research seeks to treat metabolic liver disease and obesity, evaluating agents that can reverse fibrosis and reduce cardiovascular risk associated with metabolic dysfunction.
Ten trials are currently enrolling patients to assess efficacy of novel metabolic modulators and lifestyle‑integrated interventions.
The site evaluates therapies that reduce clot burden and improve pulmonary outcomes in acute vascular events affecting the lungs.
A focused program of 5 trials examines reduced‑dose thrombolysis and anticoagulant strategies, aiming to balance efficacy with safety.
Efforts concentrate on targeted and immune‑based treatments for aggressive skin cancers, with the objective of achieving deeper responses and lasting remission.
About 8 trials test checkpoint inhibitors, antibody‑drug conjugates and pathway‑specific inhibitors in these malignancies.
Investigations aim to control chronic viral infections and prevent disease progression through antiviral and immunomodulatory strategies.
Four clinical studies assess novel antivirals and combination regimens to achieve viral suppression and improve liver outcomes.
Clinical trials currently enrolling participants at this site.
GermanyA Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety
GermanyA Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis
GermanyStudy of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
GermanyStudy on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease
GermanyStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
GermanyStudy on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet
GermanyA Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer
GermanyAdjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma
GermanyStudy of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
GermanyPhase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)
GermanyEfficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
